BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 29610456)

  • 21. Discovery and validation of methylation signatures in blood-based circulating tumor cell-free DNA in early detection of colorectal carcinoma: a case-control study.
    Sui J; Wu X; Wang C; Wang G; Li C; Zhao J; Zhang Y; Xiang J; Xu Y; Nian W; Cao F; Yu G; Lou Z; Hao L; Liu L; Li B; Zhang Z; Cai S; Liu H; Lan P; Zhang W
    Clin Epigenetics; 2021 Feb; 13(1):26. PubMed ID: 33536049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum methylation levels of TAC1. SEPT9 and EYA4 as diagnostic markers for early colorectal cancers: a pilot study.
    Liu Y; Tham CK; Ong SY; Ho KS; Lim JF; Chew MH; Lim CK; Zhao Y; Tang CL; Eu KW
    Biomarkers; 2013 Aug; 18(5):399-405. PubMed ID: 23862763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer.
    Warren JD; Xiong W; Bunker AM; Vaughn CP; Furtado LV; Roberts WL; Fang JC; Samowitz WS; Heichman KA
    BMC Med; 2011 Dec; 9():133. PubMed ID: 22168215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer.
    Tham C; Chew M; Soong R; Lim J; Ang M; Tang C; Zhao Y; Ong SY; Liu Y
    Cancer; 2014 Oct; 120(20):3131-41. PubMed ID: 24925595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous Analysis of SEPT9 Promoter Methylation Status, Micronuclei Frequency, and Folate-Related Gene Polymorphisms: The Potential for a Novel Blood-Based Colorectal Cancer Biomarker.
    Ravegnini G; Zolezzi Moraga JM; Maffei F; Musti M; Zenesini C; Simeon V; Sammarini G; Festi D; Hrelia P; Angelini S
    Int J Mol Sci; 2015 Dec; 16(12):28486-97. PubMed ID: 26633373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SEPT9: A Specific Circulating Biomarker for Colorectal Cancer.
    Song L; Li Y
    Adv Clin Chem; 2015; 72():171-204. PubMed ID: 26471083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma.
    Kneip C; Schmidt B; Seegebarth A; Weickmann S; Fleischhacker M; Liebenberg V; Field JK; Dietrich D
    J Thorac Oncol; 2011 Oct; 6(10):1632-8. PubMed ID: 21694641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies.
    Ladabaum U; Allen J; Wandell M; Ramsey S
    Cancer Epidemiol Biomarkers Prev; 2013 Sep; 22(9):1567-76. PubMed ID: 23796793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case-control study.
    Ørntoft MB; Nielsen HJ; Ørntoft TF; Andersen CL;
    BMC Cancer; 2015 Oct; 15():819. PubMed ID: 26514170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis.
    Song L; Jia J; Peng X; Xiao W; Li Y
    Sci Rep; 2017 Jun; 7(1):3032. PubMed ID: 28596563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A systematic review of the performance of the SEPT9 gene methylation assay in colorectal cancer screening, monitoring, diagnosis and prognosis.
    Song L; Yu H; Jia J; Li Y
    Cancer Biomark; 2017; 18(4):425-432. PubMed ID: 28128742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites.
    Jung M; Pützer S; Gevensleben H; Meller S; Kristiansen G; Dietrich D
    Clin Epigenetics; 2016; 8():24. PubMed ID: 26937257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions.
    Tänzer M; Balluff B; Distler J; Hale K; Leodolter A; Röcken C; Molnar B; Schmid R; Lofton-Day C; Schuster T; Ebert MP
    PLoS One; 2010 Feb; 5(2):e9061. PubMed ID: 20140221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circadian Rhythm of Methylated Septin 9, Cell-Free DNA Amount and Tumor Markers in Colorectal Cancer Patients.
    Tóth K; Patai ÁV; Kalmár A; Barták BK; Nagy ZB; Galamb O; Wichmann B; Tulassay Z; Molnár B
    Pathol Oncol Res; 2017 Jul; 23(3):699-706. PubMed ID: 28035516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiplex methylated DNA testing in plasma with high sensitivity and specificity for colorectal cancer screening.
    Zhao G; Li H; Yang Z; Wang Z; Xu M; Xiong S; Li S; Wu X; Liu X; Wang Z; Zhu Y; Ma Y; Fei S; Zheng M
    Cancer Med; 2019 Sep; 8(12):5619-5628. PubMed ID: 31407497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The performance of the mSEPT9 assay is influenced by algorithm, cancer stage and age, but not sex and cancer location.
    Song L; Jia J; Yu H; Peng X; Xiao W; Gong Y; Zhou G; Han X; Li Y
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):1093-1101. PubMed ID: 28224298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined SEPT9 and BMP3 methylation in plasma for colorectal cancer early detection and screening in a Brazilian population.
    Lima AB; Dos Reis MB; Matsushita M; Dos Reis MT; de Oliveira MA; Reis RM; Guimarães DP
    Cancer Med; 2023 Aug; 12(15):15854-15867. PubMed ID: 37338022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of droplet digital polymerase chain reaction of plasma methylated septin 9 on detection and early monitoring of colorectal cancer.
    Ma ZY; Chan CSY; Lau KS; Ng L; Cheng YY; Leung WK
    Sci Rep; 2021 Dec; 11(1):23446. PubMed ID: 34873218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic Assessment of septin9 DNA Methylation for Colorectal Cancer Using Blood Detection: A Meta-Analysis.
    Sun G; Meng J; Duan H; Zhang D; Tang Y
    Pathol Oncol Res; 2019 Oct; 25(4):1525-1534. PubMed ID: 30488278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of the SHOX2 and RASSF1A methylation levels with the pathological evolution of early-stage lung adenocarcinoma.
    Zhao J; Lu Y; Ren X; Bian T; Feng J; Sun H; Liu L; She B; Liu Y; Ke H
    BMC Cancer; 2024 Jun; 24(1):687. PubMed ID: 38840077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.